Vigabatrin is an inhibitor of γ-aminobutyric acid transaminase. The purpose of these analyses was to develop a population pharmacokinetics model to characterize the vigabatrin concentration–time profile for adults and children with refractory complex partial seizures (rCPS) and for children with infantile spasms (IS); to identify covariates that affect its disposition, and to enable predictions of systemic vigabatrin exposure for patients 1–12 months of age.
2014 年 11 月 1 日
Author(s): Jace Nielsen, Kenneth Kowalski, Aziz Karim, Mahlaqa Patel, David Wesche, Dwain Tolbert
Year: 2014 年 11 月 1 日